The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. — VialBase Research

Summary

Cellular senescence is a central contributor to the aging phenotype, and the same group’s earlier work identified the FOXO4-p53 axis as pivotal for maintaining the viability of senescent cells — the basis for targeting those cells with the senolytic peptide FOXO4-DRI. This paper resolves the molecular details of that interaction. Using solution NMR, the authors solved structural models of the p53 transactivation domain in complex with the FOXO4 forkhead domain and, separately, in complex with FOXO4-DRI. The striking result is that the disordered FOXO4-DRI peptide binds the disordered p53TAD2 region and forms a transiently folded complex, rather than the rigid lock-and-key arrangement typical of structured protein interfaces. Both components of the therapeutic construct contribute to binding: the FOXO4-derived region and the cationic cell-permeability peptide that was added to get the molecule into cells. The authors also showed that phosphorylation of p53 enhances its affinity for both native FOXO4 and FOXO4-DRI, which is mechanistically important because p53 is heavily phosphorylated in stressed and senescent cells. The stated purpose of the work is to provide a foundation for developing p53 inhibitors to treat senescence-linked diseases such as cancers. This is a purified-protein biophysics study — no cells, animals, or humans were treated, and it contains no efficacy or safety information.

Key Findings

• Solution NMR structural models were solved for the p53 transactivation domain bound to the FOXO4 forkhead domain and for the same domain bound to FOXO4-DRI
• The disordered FOXO4-DRI binds the disordered p53TAD2 and forms a transiently folded complex — an intrinsically disordered protein interaction rather than a rigid structured interface
• Both the FOXO4-derived region and the cationic cell-permeability peptide contribute to the binding interaction, meaning the delivery tag is not inert to the pharmacology
• p53 phosphorylation enhances affinity for both FOXO4 and FOXO4-DRI, linking binding strength to the stress state of the cell
• The authors frame the work as the basis for developing p53 inhibitors to treat diseases linked to cellular senescence such as cancers — the intended translational target is oncology, not consumer anti-aging
• No cellular, animal, or human component; no dosing, pharmacokinetic, efficacy, or safety data

Relevance to Foxo4-DRI

This is the best mechanistic explanation of what Foxo4-DRI is and how it works: a disordered peptide that engages the disordered transactivation domain of p53 in a transient complex, with affinity that increases when p53 is phosphorylated. Two details are worth carrying forward. First, the cationic cell-permeability tag — usually described as a mere delivery vehicle — participates directly in target binding, so it is part of the active pharmacophore rather than packaging. Second, the authors position this work as groundwork for p53 inhibitor development in cancer, not as validation of an anti-aging product. Understanding the mechanism at atomic resolution is not the same as knowing what the compound does in a body, and this paper supplies precisely zero evidence on that question. It should be cited for mechanism only, never as support for efficacy or safety.

Citation

Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications. 2025;16(1):5672. doi:10.1038/s41467-025-60844-9.

See Also

• Parent compound: Foxo4-DRI